As pessimistic as I am about this company, I have to agree with ememem here. I am certain that a tag from a CEO splashed on the front page of a website has some bearing of diligence. Not to mention that a high profile charity such as the MIchael J. Fox Foundation would also clearly perform their due diligence well before cutting a check or singing the potential praises of the ampakine platform. I'm not sure how many projects MJFF is currently funding, but Cortex may have found their money tree within the Michael J. Fox Foundation for future development of other indications. Something is most definitely brewing here. Whether it comes to pass in a timely fashion without further dilution to the shareholder remains to be seen. <--- That's a laughable statement at best.
"The Michael J. Fox Foundation will do whatever it takes to speed promising Parkinson's research toward clinical testing and patients. While our strong emphasis is on translational and clinical research, we also fund high-risk/high-reward discovery work to help keep novel approaches flowing into the drug development pipeline. New funding initiatives are announced throughout the year. Sign up to receive e-mail alerts whenever a new program is announced."
"The Michael J. Fox Foundation is helping to speed up drug development for PD with innovative strategies that identify roadblocks along the therapeutic development pipeline. By sharing the risk of drug development with academic and industry researchers alike, we hope to increase the movement of new treatments into the clinic."
Market Data 
Markets 
AI
